Rituxan (rituximab)

A 77-year-old woman with stage IV serous endometrial carcinoma presented 24 days after a single dose of carboplatin, paclitaxel, and pembrolizumab, with progressive weakness, ptosis, diplopia, and respiratory compromise...She was treated with pulse corticosteroids and plasma exchange (PLEX), with rituximab added after the second session for an inadequate response. Persistent myocarditis with sustained troponin elevation prompted further escalation to abatacept and ruxolitinib...The case is distinguished by refractory disease requiring four sequential lines of immunosuppression, concurrent immune-mediated hepatitis and thyroiditis, and a seronegative myasthenia gravis profile, consistent with the more heterogeneous, non-antibody-mediated mechanisms increasingly recognized in ICI-induced disease. It informs treatment escalation in refractory cases and underscores three principles essential to managing this high-mortality syndrome: early recognition, systematic screening for all syndromic components once any one is identified, and timely escalation through multiple lines of immunosuppression when disease proves refractory.

P2/3, N=960, Not yet recruiting, Merck Sharp & Dohme LLC

We leveraged the Phase III Fondazione Italiana Linfomi FOLL12 trial, which treated patients with advanced-stage FL with R-CHOP or R-Bendamustine, to evaluate the role of myeloid CH at baseline and after chemoimmunotherapy (CIT). Patients acquiring fit DDR clones (N = 37) had inferior long-term outcomes, including independent increased risk of second malignancies (hazard ratio [HR] 2.63, P = 0.035) that developed in 28 patients, and shorter OS (HR 3.28, P = 0.008). CH emerges as a novel and potentially valuable biomarker in FL, capable of predicting long-term toxicities that are key endpoints in indolent lymphoid malignancies characterized by long-lasting survival.

Second, a network meta-analysis ranked the efficacy and safety of regimens including rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R); R-CHOP plus lenalidomide (R2-CHOP); R-CHOP plus ibrutinib (I+R-CHOP); R-CHOP plus zanubrutinib (Z+R-CHOP); and R-CHOP plus venetoclax (Ven-R-CHOP). DEL is a distinct high-risk subtype with quantifiable prognostic detriment. Z+R-CHOP emerges as a promising strategy requiring validation in prospective studies.

He received intensive multimodal immunotherapy, including high-dose methylprednisolone, intravenous immunoglobulin, plasma exchange, and rituximab. This is the first report of a seizure-free, triple-positive autoimmune encephalitis subtype presenting with prominent cognitive impairment, thereby expanding the clinical spectrum of recently described overlapping autoimmune encephalitis syndromes. The low titer and rapid seroreversion of mGluR5 antibodies suggest a possible bystander phenomenon secondary to blood-brain barrier disruption.

However, interpretation of these findings is limited by the non-randomized design and differences in rituximab exposure between groups, which may have contributed to the observed outcomes and limited definitive conclusions. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

Later, the patient received systemic chemotherapy with R-CHOP for eight cycles...This case presents unique features such as chronic abdominal pain and anorexia, which can lead to misdiagnosis due to a broad differential. There is a need to provide knowledge of primary colon lymphoma to ensure early diagnosis and favorable outcomes.

We summarize pivotal translational inflection points, from rituximab extension beyond lymphoma to approvals of ocrelizumab, ofatumumab, ublituximab, and inebilizumab in neuroimmunology. We further review plasma cell-directed and T-cell-engaging strategies for deep immune resets in refractory disease, while clarifying implications for trial design, long-term safety, and implementation. Finally, we introduce a model-informed roadmap integrating population PK/PD, exposure-response, and quantitative systems pharmacology to optimize indication selection, patient enrichment, and dose/regimen design-supporting confident extrapolation rather than empiricism.

P2, N=71, Active, not recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Dec 2026 --> Jun 2027

METTL3 may drive DE-DLBCL cell cycle progression and RTX resistance by activating MYC and BCL2 transcription via YTHDF2-mediated m6A modification of β-catenin, revealing a novel mechanism of indirect transcriptional regulation in lymphoma and a potential therapeutic target.

Time-limited BR-VR achieved high uMRD rates and durable remissions with a manageable safety profile. While the treatment landscape in CLL has largely shifted toward chemotherapy-free regimens, these data demonstrate the biological proof-of-concept that limited induction chemotherapy can effectively mitigate TLS risk and facilitate safe outpatient ramp-up of venetoclax.

A 71-year-old woman was diagnosed with FL grade 3A and received chemotherapy with rituximab...Our experience underscores that rapid clinical deterioration (e.g., fever, hepatosplenomegaly, or B symptoms) during the course of FL should prompt consideration of EBV-associated lymphoma in the differential diagnosis, alongside histologic transformation. Further case reports and molecular analyses should help improve diagnostic accuracy and establish treatment strategies for this rare and aggressive disease.